Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates

分组1 - Monte Rosa Therapeutics reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.47, and a significant decline from earnings of $0.23 per share a year ago, resulting in an earnings surprise of -17.02% [1] - The company posted revenues of $2.78 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 72.9%, and a sharp decline from year-ago revenues of $60.65 million [2] - The stock has added about 4.3% since the beginning of the year, contrasting with the S&P 500's decline of 2.1% [3] 分组2 - The earnings outlook for Monte Rosa Therapeutics is uncertain, with current consensus EPS estimates of -$0.29 on $20.86 million in revenues for the coming quarter and -$1.03 on $96.21 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 43% of over 250 Zacks industries, indicating potential challenges for the stock's performance [8] - The estimate revisions trend for Monte Rosa Therapeutics was unfavorable ahead of the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]